Abivax S.A. Form 20-F Summary (Fiscal Year Ended December 31, 2025)
Business Context and Reporting Period
Company: Abivax S.A. (French biotechnology company, dual-listed on Euronext Paris and Nasdaq Global Market under symbol ABVX).
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: Clinical-stage biotechnology focused on developing therapeutics for chronic inflammatory diseases, specifically Inflammatory Bowel Diseases (IBD).
Lead Asset: Obefazimod (ABX464), an oral small molecule enhancing miR-124 expression, currently in Phase 3 development for Ulcerative Colitis (UC) and Phase 2b for Crohn's Disease (CD).
Key Milestone: In July 2025, the company announced positive top-line results from two Phase 3 induction trials (ABTECT-1 and ABTECT-2) for UC, demonstrating statistically significant clinical remission rates compared to placebo.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (€ millions) | 2024 (€ millions) | 2023 (€ millions) |
|---|---|---|---|
| Total Operating Income | 4.6 | 12.4 | 4.6 |
| Total Operating Expenses | (250.6) | (185.4) | (132.0) |
| Research & Development (R&D) | (177.8) | (146.5) | (103.2) |
| General & Administrative (G&A) | (67.7) | (32.9) | (22.4) |
| Operating Loss | (246.1) | (173.0) | (127.4) |
| Net Loss | (336.1) | (176.2) | (147.7) |
| Cash & Cash Equivalents (End of Period) | 516.7 | 144.2 | 251.9 |
| Accumulated Tax Losses | 912.9 | 609.4 | 459.8 |
Note: All figures in Euros. The 2025 Net Loss includes significant non-cash financial expenses related to the fair value remeasurement of convertible notes and warrants prior to conversion, as well as increased employer taxes on share-based compensation due to share price appreciation.
Material Changes vs. Prior Period
- Revenue: No product revenue generated in 2025, 2024, or 2023. Operating income consists of research tax credits (CIR), subsidies, and depositary fees.
- Expense Growth: Operating expenses increased 35% year-over-year (YoY).
- R&D: Increased 21% YoY, driven by the progression of Phase 3 UC trials, initiation of Phase 2b CD trials, and increased Chemistry, Manufacturing, and Controls (CMC) costs.
- G&A: Increased 105% YoY, primarily due to a sharp rise in employer taxes and social contributions related to share-based compensation (Free Shares/AGA) triggered by the significant increase in share price following the July 2025 Phase 3 data readout.
- Financial Loss: Net financial loss widened significantly to €84.2 million (vs. €3.3 million in 2024). This was driven by:
- Increases in the fair value of senior convertible notes (Heights) and warrants (Kreos/Claret) prior to their conversion into equity.
- Foreign exchange losses of €13.4 million.
- Interest expenses on royalty certificates and debt instruments.
- Liquidity: Cash position increased substantially to €516.7 million, bolstered by a €637.5 million gross proceeds follow-on offering in July 2025 and the conversion of debt instruments into equity.
Guidance, Outlook, and Management Commentary
- Clinical Outlook:
- UC: Top-line data from the Phase 3 ABTECT maintenance trial is expected in late Q2 2026. Assuming positive results, the company plans to submit a New Drug Application (NDA) to the FDA in Q4 2026.
- CD: Phase 2b induction trial top-line results are expected in Q4 2026.
- Combination Therapy: Evaluating combination therapies (e.g., with etrasimod) with preclinical data expected in 2026.
- Capital Resources: Management estimates that existing cash and short-term investments (€530.4 million as of Dec 31, 2025) are sufficient to fund operations into Q4 2027, providing a runway of over 12 months post-NDA submission.
- Debt Status: The company successfully converted or prepaid all major debt instruments (Heights Convertible Notes, Kreos/Claret OCABSA, and Tranches B/C bonds) during 2025, resulting in zero outstanding debt from these facilities as of year-end.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting as of December 31, 2025, related to risk assessment, control activities, information/communication, and monitoring. Remediation efforts are ongoing but not yet complete.
Investor Verification Checklist
- Clinical Data Verification: Verify the statistical significance and safety profile of the Phase 3 ABTECT induction data announced in July 2025 and monitor the upcoming Phase 3 maintenance data readout (expected Q2 2026).
- Regulatory Timeline: Confirm the timeline for the FDA NDA submission (targeted Q4 2026) and potential interactions with the EMA.
- Internal Control Remediation: Monitor the progress of remediation for the disclosed material weaknesses in internal controls over financial reporting to ensure future reporting reliability.
- Share-Based Compensation Impact: Assess the ongoing impact of share price volatility on G&A expenses due to employer tax liabilities on free share plans (AGA).
- Intellectual Property: Review the patent portfolio expiration dates (composition of matter patents expire in 2030; method of use patents in 2035) and the status of patent term extension applications.
- Geopolitical Risks: Evaluate the impact of the Russia-Ukraine conflict on clinical trial sites in Ukraine (though the company has excluded Russia/Belarus from Phase 3 and maintains remote monitoring for Ukrainian sites).